COMPREHENSIVE PHARMACOLOGIC MANAGEMENT OF OVERACTIVE BLADDER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Overactive bladder (OAB) is a common and bothersome condition manifested by urgency, frequent urination, significantly impairing patients’ quality of life. The article presents an overview of the evidence on pharmacotherapy of neurogenic and idiopathic OAB. Selective M3 receptor blockers have been shown to be the medications of choice in treating these patients. Many studies have shown that solifenacin 10 mg is a starting dose for patients with OAB. Mirabegron (Betmiga) is the only β3-adrenergic receptor agonist approved for primary treatment of OAB patients refractory to anticholinergics or have their side effects. It seems promising to use this drug, both as monotherapy and concurrently with anticholinergic agents to improve treatment results in patients with idiopathic and neurogenic OAB.

Full Text

Restricted Access

About the authors

G. G Krivoborodov

N.I. Pirogov RNRMU of Minzdrav of Russia; Russian Gerontology Research and Clinical Center

Email: dr.krivoborodov@yandex.ru
Dr.Med.Sci., Prof. at the Department of Urology and Andrology, Medical Faculty; Head of the Department of Urology Moscow, Russia

E. I Tur

Universita’ degli studi di Firenze

PhD, Urologist Florence, Italy

References

  1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
  2. Haylen B.T., de Ridder D., Freeman R.M., Swift S.E., Berghmans B., Lee J., Monga A., Petri E., Rizk D.E., Sand P.K., Schaer G.N. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfimct. 2010;21:5-26.
  3. Mazo E.B., Krivoborodov G.G. Overactive bladder. M. Veche. 2003; 160 p. Russian (Мазо Е.Б., Кривобородов Г.Г. Гиперактивный мочевой пузырь. М. Вече. 2003;160 с.).
  4. Kuz’min I.V. Assessing the quality of life in patients with overactive bladder. Nefrologiya. 2006; 10(4):93-97. Russian (Кузьмин И.В. Оценка качества жизни у больных с гиперактивностью мочевого пузыря. Нефрология. 2006;10(4):93-97).
  5. Tran K., Levin R.M., Mousa S.M. Behavioral Intervention versus Pharmacotherapy or Their Combinations in the Management of Overactive Bladder Dysfunction. The Pharmaceutical Research Institute. - Albany College of Pharmacy and Health Sciences, Rensselaer, NY 12144, USA. July 7, 2009.
  6. Guidelines EAU. 2016.
  7. Cardozo L., Lisec M., Millard R., van Vierssen Trip O., Kuzmin I., Drogendijk T.E., Huang M., Ridder A.M. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004;172:1919-1924.
  8. Chapple C.R., Rechberger T., Al-Shukri S., Meffan P., Everaert K., Huang M., Ridder A. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004;93:303-310.
  9. Chapple C.R., Cardozo L., Steers W.D., Govier F.E. Solifenacin significantly improves all symptoms of overactive bladder syndrome. Int J Clin Pract 2006;60:959-966.
  10. Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study. Int J Gynaecol Obstetr. 2003;83:94.
  11. Cardozo L., Castro-Diaz D., Gittelman M., Ridder A., Huang M. Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 2006;17:512-519.
  12. Chapple C.R., Martinez-Garcia R., Selvaggi L., Toozs-Hobson P., Warnack W., Drogendijk T., Wright D.M., Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-470.
  13. Chapple C.R., Fianu-Jonsson A., Indig M., Khullar V., Rosa J., Scarpa R.M., Mistry A., Wright D.M., Bolodeoku J. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol. 2007;52:1195-1203.
  14. Chu F., Smith N., Uchida T. Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder. Curr Ther Res Clin Exp. 2009;70(6):405-420.
  15. Chapple C.R., Rosenberg M.T., Brenes F.J. Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int. 2009;104:960-967.
  16. Cardozo L., Amarenco G., Pushkar D., Mikulas J., Drogendijk T., Wright M., Compion G. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). BJU Int. 2013;111(5):804-810.
  17. Amarenco G., Sutory M., Zachoval R., Agarwal M., Del Popolo G., Tretter R., Compion G., De Ridder D. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity: Results from the double-blind, randomized, active- and placebo-controlled SONIC urodynamic study. Neurourol Urodyn. 2015.
  18. van Rey F., Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753.
  19. Becker B.J. Synthesizing standardized mean change measures. Br J Math Stat Psychol. 1988;41:257e78.
  20. Zesiewicz T.A., Evatt M., Vaughan C.P. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord. 2015;21(5):514-520.
  21. Drake M.J., Chapple C., Sokol R. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension. Eur Urol. 2015;67(2):262-270.
  22. Chapple C.R., Amarenco G., Lopez Aramburu M.A., Everaert K., Liehne J., Lucas M., Vik V., Ridder A., Snijder R., Yamaguchi O. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. 2013;32(8):1116-1122.
  23. Chapple C.R., Dvorak V., Radziszewski P., Van Kerrebroeck P., Wyndaele J.J., Bosman B., Boerrigter P., Drogendijk T., Ridder A., Van Der Putten-Slob I., Yamaguchi O. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. 2013;24(9):1447-1458.
  24. Khullar V., Amarenco G., Angulo J.C., Cambronero J., Hoye K., Milsom I., Radziszewski P., Rechberger T., Boerrigter P., Drogendijk T., Wooning M., Chapple C. Efficacy and tolerability of mirabegron, a ß(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283-295.
  25. Chapple C.R., Kaplan S.A., Mitcheson D., Klecka J., Cummings J., Drogen dijk T., Dorrepaal C., Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a ß3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296-305.
  26. Chapple C.R., Cardozo L., Nitti V.W., Siddiqui E., Michel M.C. Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17-30
  27. Nitti V.W., Rosenberg S., Mitcheson D.H., He W., Fakhoury A., Martin N.E. Urodynamics and safety of the ß3-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320-1327.
  28. Abrams P., Kelleher C., Staskin D., Rechberger T., Kay R., Martina R., Newgreen D., Paireddy A., van Maanen R., Ridder A. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67(3):577-588.
  29. Drake M.J., Chapple C., Esen A.A., Athanasiou S., Cambronero J., Mitcheson D., Herschorn S., Saleem T., Huang M., Siddiqui E., Stölzel M., Herholdt C., MacDiarmid S. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70(1):136-145.
  30. Wada N., Okazaki S., Kobayashi S., Hashizume K., Kita M., Matsumoto S., Kakizaki H. Efficacy of combination therapy with mirabegron for anticholinergic-resistant neurogenic bladder: videourodynamic evaluation. Hinyokika Kiyo. 2015;61(1):7-11.
  31. Andretta E., Virdone S., Filocamo M.T. et al. Mirabegron and refractory neurogenic urinary incontinence. Eur Urol. 2016;15(Suppl. 3):e656
  32. Wöllner J., Pannek J. Initial experience with the treatment of neurogenic detrusor overactivity with a new β-З agonist (mirabegron) in patients with spinal cord injury. Spinal Cord. 2016;54:78-82.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies